Skip to content Skip to navigation

Therapeuic Programmes

Ablynx
Ablynx
Ablynx nv Technologiepark 4 Ghent/Zwijnaarde, 9052 Belgium

Ablynx is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases. Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. The unique structure and stability of Nanobodies® has allowed Ablynx, and its partners, to pursue targets that are typically difficult to reach with conventional antibodies.